BrightGene Bio Medical Technology C (688166.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE100003PR1

Price
29.93 CNY
Market cap
12.64 bn CNY
P/E (2025)
–
P/S (2025)
10.33
Dividend yield
0.05 %
Net margin
4.46 %
Return on equity (ROE)
1.92 %
Return on assets (ROA)
0.94 %

BrightGene Bio Medical Technology C financials

Fiscal year20242025
Revenue1.28 bn CNY1.22 bn CNY
Gross profit737.60 m CNY622.03 m CNY
Operating income250.83 m CNY110.20 m CNY
EBIT209.64 m CNY76.87 m CNY
Net income189.17 m CNY54.51 m CNY
Diluted EPS – continuing operations0.45 CNY–

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About BrightGene Bio Medical Technology C

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, including metabolism, oncology, respiratory, immunosuppression, antiviral, antifungal, antitumor, cerebrovascular, iron supplement, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, digestion, and others. In addition, the company is involved in technology research and development; transfer of biomedical products; import, export, wholesale, and retail of medicines; production and operation of medical devices; and technical services. BrightGene Bio-Medical Technology Co., Ltd. was founded in 2001 and is based in Suzhou, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.